Dendritic cells, headhunters for anti-tumor CD8+ T cells in triple-negative breast cancer

Abstract

How do we identify patients most likely to benefit from immune checkpoint blockade therapies? This month in Med, Wu and colleagues1 identify that CCL19+ mature dendritic cells correlated with responses to anti-PD-(L)1 immunotherapy in triple-negative breast cancer patients, suggesting the use of CCL19 as a biomarker to predict patient outcomes.

CITA DEL ARTÍCULO Med. 2023 Jun 9;4(6):341-343. doi: 10.1016/j.medj.2023.05.004.